Clinical trials: Disorder of the Lower Urinary Tract
Urinary Bladder, Overactive
An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants
The objective of this study is to evaluate the efficacy of oxybutynin chloride oral osmotic therapeutic system (OROS) on patient-reported outcomes after 12 weeks of treatment by dose escalation in participants with overactive…
- Trial name
- NCT00613327
- Testing
- Oxybutynin chloride OROS
- Volunteers
- 345 people
- Sponsor
- Janssen Korea, Ltd., Korea
Overactive Bladder
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
- Trial name
- VECTOR (NCT00431041)
- Testing
- solifenacin, oxybutynin immediate release
- Where
- 12 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Astellas Pharma Inc
Refractory Overactive Bladder
A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB) With X-Ray Guided Technique
Overactive bladder(OAB,Urgency) was determined by International Continence Society as Urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract…
- Trial name
- NCT02946723
- Testing
- ultrasound, X-ray
- Volunteers
- 30 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Urinary Bladder, Overactive
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
This is an open-label extension study intended for subjects who have previously completed study A0221045 (fesoterodine in elderly OAB patients) and who have been recommended by the investigator as being suitable for the extended…
- Trial name
- NCT01054222
- Testing
- Fesoterodine
- Where
- 3 sites in Portugal
- Volunteers
- 31 people
- Sponsor
- Pfizer
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
MCS in the Treatment of Lower Urinary Tract Symptoms
The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
- Trial name
- MCS_LUTS (NCT01002417)
- Testing
- MCS-2 15 mg/day, MCS-2 30 mg/day
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Female Stress Incontinence, Stress Urinary Incontinence
Biological Sling Allograft (UVT) for the Treatment of Urinary Incontinence in Women Presenting With Synthetic Sling Complications
The purpose of this open, multi center trial is to evaluate a new biological replacement for synthetic slings in the treatment of female stress urinary incontinence.
- Trial name
- NCT05207189
- Testing
- UVT
- Where
- 3 sites in France
- Volunteers
- 16 people
- Sponsor
- TBF Genie Tissulaire
Stress Urinary Incontinence
Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
This randomized, double-blind, placebo-controlled, multicenter, confirmatory study will evaluate the efficacy and safety of Cook MyoSite Incorporated Autologous Muscle-Derived Cells (generic name Iltamiocel) compared to a placebo…
- Trial name
- NCT01893138
- Testing
- Iltamiocel
- Where
- 29 sites in United States, Belgium and 1 more
- Volunteers
- 311 people
- Sponsor
- Cook MyoSite
Urinary Bladder, Overactive, Overactive Bladder
Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients
The purpose of the study is to assess patient's persistency in maintaining solifenacin treatment for overactive bladder.
- Trial name
- NCT00985387
- Testing
- Solifenacin
- Where
- 41 sites in South Korea
- Volunteers
- 1,215 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia, BPH
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Conditions
- Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
- Trial name
- NCT01846793
- Testing
- NX-1207
- Where
- 17 sites in United States
- Volunteers
- 160 people
- Sponsor
- Nymox Corporation
Overactive Bladder
Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.
With this study researchers want to gather information about the consumer use behavior of Oxytrol in a simulated setting in which the medicine is sold directly to a consumer without a prescription from a healthcare professional.
- Trial name
- NCT04534491
- Testing
- Oxybutynin (Oxytrol, BAY839380)
- Where
- United States
- Volunteers
- 855 people
- Sponsor
- Bayer
Stress Urinary Incontinence
A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence (Urinary Leakage)
Stress urinary incontinence affects nearly 30 million women worldwide and the main goal of surgical treatment is to stop urinary incontinence (urinary leakage) that occurs with physical activity, coughing, sneezing, etc.Patients…
- Trial name
- NCT00196521
- Testing
- Tension-free vaginal tape obturator system
- Where
- 19 sites in United States, Canada and 5 more
- Volunteers
- 300 people
- Sponsor
- Ethicon, Inc.
Stress Urinary Incontinence, Sexual Dysfunction
Safety, Efficacy and Usage Compliance of the Silk'n Tightra Device
This is an open label, prospective study aimed to evaluate safety and efficacy of the Silk'n Tightra device for improvement of sexual functioning, vulvovaginal appearance and reduction of SUI.
- Conditions
- Stress Urinary Incontinence, Sexual Dysfunction, Vulvovaginal Atrophy
- Trial name
- NCT03900143
- Testing
- Tightra vaginal device
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Home Skinovations Ltd.
Benign Prostatic Hyperplasia
Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)
This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign…
- Trial name
- NCT01460342
- Testing
- Tadalafil
- Where
- 17 sites in Japan, South Korea
- Volunteers
- 610 people
- Sponsor
- Eli Lilly and Company
Overactive Bladder
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
This is a two-part study. Part 1 is designed to find the best modified release formulation of GW423753; Part 2 is designed to use the selected formulation(s) from Part 1 to find out if food affects the way the medication is…
- Trial name
- NCT00427596
- Testing
- Solabegron
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Stress Urinary Incontinence
Post-Market Clinical Follow-Up onTVT EXACT® Continence System
The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT EXACT® Continence System in women undergoing retropubic mid-urethral sling surgery for Stress Urinary Incontinence (SUI).
- Trial name
- NCT04829994
- Testing
- Intervention
- Where
- 8 sites in United States, Austria and 4 more
- Volunteers
- 198 people
- Sponsor
- Ethicon, Inc.
Stress Urinary Incontinence, Radical Prostatectomy
Feasibility Study of A VoRo UrologIc ScaffolD (ARID)
The objective of this study is to evaluate the safety and performance of the Voro Urologic Scaffold as a prophylactic treatment for post-prostatectomy stress urinary incontinence.
- Trial name
- ARID (NCT06275945)
- Testing
- Voro Urologic Scaffold
- Where
- Panama
- Volunteers
- 40 people
- Sponsor
- Levee Medical, Inc.
Benign Prostatic Hyperplasia
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Trial name
- NCT01438775
- Testing
- NX-1207
- Where
- 28 sites in United States
- Volunteers
- 192 people
- Sponsor
- Nymox Corporation
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.
- Conditions
- Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
- Trial name
- SYNERGY (NCT01972841)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 435 sites in United States, Argentina and 40 more
- Volunteers
- 3,527 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Incontinence, Multiple Sclerosis
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
- Conditions
- Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
- Trial name
- NCT01600716
- Testing
- OnabotulinumtoxinA
- Where
- 10 sites in United States, Belgium and 6 more
- Volunteers
- 144 people
- Sponsor
- Allergan
Overactive Bladder
Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms
To evaluate the safety and durability of the TheraNova Neuromodulation System in overactive bladder (OAB) patients.
- Trial name
- NCT05162833
- Testing
- TheraNova Neuromodulation Device
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Theranova, L.L.C.